OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial

NCT06558214 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Glioblastoma

Interventions

DRUG: Pembrolizumab
DEVICE: Optune GIO®
DEVICE: NeuroBlate®

Sponsor

University of Florida